Share the post "DII Data: Stock Market today Insights for 15 Jul 2024"
| Comapny Logo | Company | Client name | Buy/Sell | Qty Traded | Price | Trader Name |
|---|---|---|---|---|---|---|
 |
Kellton Tech Solutions Ltd. | Bofa Securities Europe Sa | BUY | 637K | 175.91 | Nk Securities Research Private Limited |
 |
JUBILANT PHARMOVA LIMITED | East Bridge Capital Master Fund Limited | SELL | 1M | 718.15 | East Bridge Capital Master Fund I Limited |
 |
Eris Lifesciences Limited | Franklin Templeton Mutual Fund | BUY | 1M | 1000.04 | Rakesh Shah |
 |
Pearl Global Industries Limited | Hdfc Mutual Fund | BUY | 447K | 731.00 | Shah Sanjiv Dhireshbhai |
 |
Kamdhenu Ventures Limited | Minerva Ventures Fund | BUY | 5M | 40.00 | Hjs Securities Private Limited |
 |
Achyut Healthcare Limited | Sera Investments & Finance India Limited | SELL | 184K | 56.00 | Isem Mehmet |
| DHYAANI TRADEVENTTURES LIMITED | Shiv Shakti Trading Company | BUY | 22K | 22.88 | Na |
The 637K shares of Kellton Tech Solutions Ltd. have been purchased by the by Bofa Securities Europe Sa through Domestic Investments at a price of ₹175.91 per shareand it is sold by Nk Securities Research Private Limited at a price of ₹175.91 per shares.
The 1M shares of JUBILANT PHARMOVA LIMITED have been sold by the by East Bridge Capital Master Fund Limited through Domestic Investments at a price of ₹718.15 per shareand it is purchased by East Bridge Capital Master Fund I Limited at a price of ₹718.15 per shares.
The 1M shares of Eris Lifesciences Limited have been purchased by the by Franklin Templeton Mutual Fund through Domestic Investments at a price of ₹1000.04 per shareand it is sold by Rakesh Shah at a price of ₹1000.04 per shares.
The 447K shares of Pearl Global Industries Limited have been purchased by the by Hdfc Mutual Fund through Domestic Investments at a price of ₹731.00 per shareand it is sold by Shah Sanjiv Dhireshbhai at a price of ₹731.00 per shares.
The 5M shares of Kamdhenu Ventures Limited have been purchased by the by Minerva Ventures Fund through Domestic Investments at a price of ₹40.00 per shareand it is sold by Hjs Securities Private Limited at a price of ₹40.00 per shares.
The 184K shares of Achyut Healthcare Limited have been sold by the by Sera Investments & Finance India Limited through Domestic Investments at a price of ₹56.00 per shareand it is purchased by Isem Mehmet at a price of ₹56.00 per shares.
The 22K shares of DHYAANI TRADEVENTTURES LIMITED have been purchased by the by Shiv Shakti Trading Company through Domestic Investments at a price of ₹22.88 per share.
Kellton Tech Solutions Ltd.
2.00
Net Sales
239.35
Net Profit
2.00
Total Income
-2.00
Expenditure
154
Current Price
1,499
Market Cap
The latest financial figures for Kellton Tech Solutions Ltd. indicate a strong performance. The company achieved net sales of ₹2.00 million and total income of ₹2.00 million for the quarter. Expenditure was ₹-2.00 million, resulting in a net profit of ₹239.35 million. Earnings per Share (EPS) for continuing operations stood at ₹2.50. The report also shows other income of ₹5.76 million, finance costs of ₹-46.82 million, and employee benefit expenses of ₹-1.00 million. Depreciation and amortization expenses totaled ₹-39.66 million. Current tax expense was ₹-9.93 million and deferred tax expense was ₹8.36 million. Total comprehensive income for the period was ₹246.72 million, with other comprehensive income net of taxes at ₹7.38 million.
The company has a market capitalization of ₹1,499 crore and a current stock price of ₹154. Historically, the stock has fluctuated between ₹184 / 72.5. With a Price-to-Earnings (P/E) ratio of 21.9, the stock appears highly valued. The book value per share is ₹45.5, and the dividend yield is 0.00%. The Return on Capital Employed (ROCE) is 16.2% and the Return on Equity (ROE) is 15.7%. The debt-to-equity ratio is very low at 0.31, although the company reports a net cash flow of ₹-2.13 crore. The Piotroski score is 5.00, and the Graham Number estimates the intrinsic value of the stock at ₹85.0. The Price-to-Book (P/B) ratio is 3.36, indicating the stock is trading at a premium relative to its book value.
Jubilant Pharmova Limited
17,317.00
Net Sales
4,818.00
Net Profit
17,457.00
Total Income
16,419.00
Expenditure
1,220
Current Price
19,424
Market Cap
The latest financial figures for Jubilant Pharmova Limited indicate a strong performance. The company achieved net sales of ₹17,317.00 million and total income of ₹17,457.00 million for the quarter. Expenditure was ₹16,419.00 million, resulting in a net profit of ₹4,818.00 million. Earnings per Share (EPS) for continuing operations stood at ₹30.44. The report also shows other income of ₹140.00 million, finance costs of ₹710.00 million, and employee benefit expenses of ₹5,529.00 million. Depreciation and amortization expenses totaled ₹907.00 million. Current tax expense was ₹261.00 million and deferred tax expense was ₹-82.00 million. Total comprehensive income for the period was ₹4,779.00 million, with other comprehensive income net of taxes at ₹-39.00 million.
Valued at ₹19,424 crore, the company's stock trades at ₹1,220, with historical highs and lows of ₹1,247 / 319. The P/E ratio of 83.0 reflects a high stock valuation. The book value is ₹341, and the dividend yield is 0.41%. ROCE is at 6.74%, and ROE is 0.76%. The company’s minimal debt-to-equity ratio of 0.67 contrasts with its negative net cash flow of ₹-57.5 crore. The Piotroski score is 8.00, and the Graham Number of ₹516 provides insight into the stock’s valuation. The Price-to-Book (P/B) ratio of 3.58 indicates a premium valuation.
Eris Lifesciences Limited
4,566.90
Net Sales
170.40
Net Profit
4,618.50
Total Income
4,350.30
Expenditure
1,448
Current Price
19,711
Market Cap
The financial snapshot for Eris Lifesciences Limited reveals a noteworthy performance this quarter. Net sales amounted to ₹4,566.90 million and total income was ₹4,618.50 million. The company's expenditure was ₹4,350.30 million, leading to a net profit of ₹170.40 million. Earnings per Share (EPS) for continuing operations were ₹1.25. The report also highlights other income of ₹51.60 million, finance costs of ₹561.70 million, and employee benefit expenses of ₹1,037.50 million. Depreciation and amortization costs were ₹455.50 million, while current and deferred taxes were ₹46.90 million and ₹50.90 million, respectively. The total comprehensive income for the period stood at ₹163.20 million, with other comprehensive income net of taxes at ₹-7.20 million.
With a market capitalization of ₹19,711 crore, the company’s stock is currently priced at ₹1,448. The historical trading range of the stock is ₹1,522 / 792. The P/E ratio is remarkably high at 52.2, suggesting a significant valuation. The book value stands at ₹190, and the dividend yield is 0.51%. The Return on Capital Employed (ROCE) is 11.3%, and the Return on Equity (ROE) is 16.3%. The debt-to-equity ratio is very low at 1.08, though the company shows a negative net cash flow of ₹38.2 crore. The Piotroski score is 4.00, with the Graham Number pegged at ₹346. The Price-to-Book (P/B) ratio of 7.62 highlights a premium valuation.
Pearl Global Industries Limited
10,528.00
Net Sales
619.29
Net Profit
10,623.83
Total Income
9,947.25
Expenditure
949
Current Price
4,352
Market Cap
The financial snapshot for Pearl Global Industries Limited reveals a noteworthy performance this quarter. Net sales amounted to ₹10,528.00 million and total income was ₹10,623.83 million. The company's expenditure was ₹9,947.25 million, leading to a net profit of ₹619.29 million. Earnings per Share (EPS) for continuing operations were ₹14.99. The report also highlights other income of ₹95.83 million, finance costs of ₹231.31 million, and employee benefit expenses of ₹1,929.04 million. Depreciation and amortization costs were ₹170.90 million, while current and deferred taxes were ₹108.99 million and ₹4.01 million, respectively. The total comprehensive income for the period stood at ₹438.16 million, with other comprehensive income net of taxes at ₹-181.13 million.
Valued at ₹4,352 crore, the company's stock trades at ₹949, with historical highs and lows of ₹1,095 / 442. The P/E ratio of 24.2 reflects a high stock valuation. The book value is ₹184, and the dividend yield is 0.92%. ROCE is at 21.4%, and ROE is 21.9%. The company’s minimal debt-to-equity ratio of 0.73 contrasts with its negative net cash flow of ₹71.8 crore. The Piotroski score is 7.00, and the Graham Number of ₹427 provides insight into the stock’s valuation. The Price-to-Book (P/B) ratio of 5.16 indicates a premium valuation.
